


1653-DFV



Appl. No. 10/612,104
Atty. Docket No. 7490MC
Amdt. dated February 10, 2005
Reply to Office Action of February 1, 2005
Customer No. 27752

Certification of Mailing or Facsimile Transmission	
I hereby certify that I have reasonable basis to expect that, on the date shown below, this correspondence is being submitted as indicated below:	
<input checked="" type="checkbox"/> mailed or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop <u>Amendment</u> , Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> facsimile transmitted to the U.S. Patent and Trademark Office via fax number (703) 879-9396	
Richard S. <u>Miller</u>	41,000
Name	Registration No. (if applicable)
<u>10 FEB 05</u>	
Date	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	:	10/612,104
Applicant(s)	:	Adam Wieslaw Mazur et al.
Filed	:	July 2, 2003
Title	:	Melanocortin Receptor Ligands
TC/A.U.	:	1653
Examiner	:	David Lukton
Conf. No.	:	3400
Docket No.	:	7490MC
Customer No.	:	27752

AMENDMENT AFTER 1ST OFFICE ACTION UNDER 37 CFR §1.111(c)

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450
Dear Sir:

In response to the Office Action of February 1, 2005, please amend the above-identified application as follows and consider the following Remarks.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 9 of this paper.

Remarks begin on page 27 of this paper.

Formal Drawings are attached following page 28 of this paper

A Statement required under 37 CFR §1.821(f) is attached following Formal Drawings.